CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants-Reference-Cited by-同舟云学术

CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants

Published:2022-04-26 Issue:2 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Martinez Maria Guadalupe¹^ORCID,Combe Emmanuel¹,Inchauspe Aurore¹²,Mangeot Philippe Emmanuel³,Delberghe Elodie¹,Chapus Fleur¹,Neveu Gregory²,Alam Antoine²,Carter Kara²,Testoni Barbara¹,Zoulim Fabien¹⁴⁵^ORCID

Affiliation:

1. INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France

2. Evotec, Lyon, France

3. Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR-5308, INSERM and Ecole Normale Superieure de Lyon, Lyon, France

4. University of Lyon, Université Claude-Bernard, Lyon, France

5. Hospices Civils de Lyon, Lyon, France

Abstract

Hepatitis B virus infection can develop into chronic infection, cirrhosis, and hepatocellular carcinoma. Treatment of chronic hepatitis B requires novel approaches to directly target the viral minichromosome, which is responsible for the persistence of the disease.

Funder

Labex DevWeCan

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.02888-21

Reference48 articles.

1. A global scientific strategy to cure hepatitis B

2. Mechanism for CCC DNA Synthesis in Hepadnaviruses

3. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg